Adagene (ADAG) Common Equity (2019 - 2026)
Adagene (ADAG) posted quarterly Common Equity of $35349.5 billion for Q4 2025, down 30.03% year-over-year from $50523.8 billion in Q4 2024, and up 93241469.26% quarter-over-quarter from $37.9 million in Q2 2025.
Adagene (ADAG) Common Equity (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Common Equity for 7 consecutive years, with $35349.5 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 30.03% year-over-year to $35349.5 billion; the TTM figure through Dec 2025 stood at $35349.5 billion (down 30.03% YoY), while the FY2025 annual figure was $35349.5 billion, down 30.03% from the prior year.
- Common Equity grew to $35349.5 billion in Q4 2025 per ADAG's latest filing, from $37.9 million in the prior quarter.
- Across five years, Common Equity topped out at $112684.1 billion in Q2 2022 and bottomed at $37.9 million in Q2 2025.
- Historically, Common Equity has averaged $28135.2 billion across 5 years, with a median of $171.4 million in 2021.
- On a YoY basis, Common Equity climbed as much as 71604497.75% in 2024 and fell as far as 100.0% in 2024.
- Adagene's Common Equity stood at $156.6 million in 2021, then tumbled by 46.93% to $83.1 million in 2022, then fell by 15.08% to $70.6 million in 2023, then jumped by 71604497.75% to $50523.8 billion in 2024, then slumped by 30.03% to $35349.5 billion in 2025.
- Business Quant data shows ADAG's Common Equity at $35349.5 billion in Q4 2025, $37.9 million in Q2 2025, and $50523.8 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 89.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.45 Mn |
| Dec 31, 2025 | 35,349.55 Bn |
| Jun 30, 2025 | 37.91 Mn |
| Dec 31, 2024 | 50,523.84 Bn |
| Jun 30, 2024 | 56.59 Mn |
| Dec 31, 2023 | 70.56 Mn |
| Jun 30, 2023 | 82,793.53 Bn |
| Dec 31, 2022 | 83.09 Mn |
| Jun 30, 2022 | 112,684.12 Bn |
| Dec 31, 2021 | 156.56 Mn |
| Jun 30, 2021 | 186.22 Mn |
| Dec 31, 2020 | -89.39 Mn |
| Dec 31, 2019 | -57.01 Mn |